Literature DB >> 22644190

Controversies in migraine: monotherapy.

Domenico D'Amico1.   

Abstract

Migraine patients with frequent and severe headaches need prophylaxis. The most used approach is monotherapy, i.e. one of the available preventive compounds is prescribed to the patient, testing its efficacy and tolerability during a treatment period of some months. Some clinicians use to add a second (or even a third) preventive compound to improve the effects of pharmacological prophylaxis, using an approach that can be defined as polytherapy. In this paper, the main advantages of monotherapy are briefly reviewed, taking into account several aspects: published evidence on polytherapy; the possibility to evaluate the adverse events of the prescribed treatment and to assess its real efficacy; the possibility of addressing different patient's needs, particularly the treatment of comorbidities and the development of an effective patient-physician communication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644190     DOI: 10.1007/s10072-012-1059-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  25 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 2.  Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach.

Authors:  Abouch Valenty Krymchantowski; Marcelo Eduardo Bigal
Journal:  Expert Rev Neurother       Date:  2006-03       Impact factor: 4.618

Review 3.  Treatment of migraine with prophylactic drugs.

Authors:  Stefan Evers
Journal:  Expert Opin Pharmacother       Date:  2008-10       Impact factor: 3.889

4.  Testing the combination beta-blocker plus topiramate in refractory migraine.

Authors:  J Pascual; M T Rivas; R Leira
Journal:  Acta Neurol Scand       Date:  2007-02       Impact factor: 3.209

5.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

6.  Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy.

Authors:  Abouch Valenty Krymchantowski; Carla da Cunha Jevoux
Journal:  Headache       Date:  2011-11-15       Impact factor: 5.887

7.  Long-term migraine prevention with topiramate: open-label extension of pivotal trials.

Authors:  Alan Rapoport; Alexander Mauskop; Hans-Christoph Diener; Susanne Schwalen; Joop Pfeil
Journal:  Headache       Date:  2006 Jul-Aug       Impact factor: 5.887

8.  Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Reto Agosti; Gianni Allais; Paul Bergmans; Gennaro Bussone; Brendan Davies; Mustafa Ertas; Michel Lanteri-Minet; Uwe Reuter; Margarita Sánchez Del Río; Jean Schoenen; Susanne Schwalen; Joop van Oene
Journal:  Lancet Neurol       Date:  2007-11-07       Impact factor: 44.182

9.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

10.  Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders.

Authors:  Abouch Valenty Krymchantowski; Carla da Cunha Jevoux; Marcelo E Bigal
Journal:  J Headache Pain       Date:  2011-10-19       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.